<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: <z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> Tu translation elongation factor (TUFM) is a nuclear encoded protein that participates in <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> <z:chebi fb="1" ids="15841">polypeptide</z:chebi> translation </plain></SENT>
<SENT sid="1" pm="."><plain>TUFM has been reported to be over-expressed in many <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> types including colorectal <z:mp ids='MP_0002038'>carcinoma</z:mp> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) by proteomics </plain></SENT>
<SENT sid="2" pm="."><plain>The present study aims to examine the prognostic implication of TUFM in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Immunohistochemical staining was performed in tissue microarrays composed of 123 cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> using a polyclonal anti-TUFM antibody </plain></SENT>
<SENT sid="4" pm="."><plain>Immunoreactivity was quantified using Image-Pro plus software, and analysed in association with patients' clinicopathological parameters and survival time </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: The immunoreactivity of TUFM was negative in 25%, weak in 50% and strong in 25% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cases </plain></SENT>
<SENT sid="6" pm="."><plain>TUFM immunoreactivity had no significant association with the clinicopathological parameters examined including TNM stage and grade </plain></SENT>
<SENT sid="7" pm="."><plain>However, strong TUFM expression significantly correlated with a higher 5-year recurrence rate (p = 0.024) </plain></SENT>
<SENT sid="8" pm="."><plain>Kaplan-Meier analysis revealed that patients with strong TUFM expression had significantly shorter <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>-specific survival than patients with negative TUFM (log-rank test, p = 0.038) </plain></SENT>
<SENT sid="9" pm="."><plain>In multivariate analysis, strong TUFM expression remained a stage-independent unfavourable prognostic indicator (p = 0.024) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Increased expression of TUFM is a promising new prognostic indicator for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Selective inhibition of TUFM in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells may present a new avenue for the targeted therapy of this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>